Ellen J. Kim

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

Sean Whittaker, Marie‐France Demierre, Ellen J. Kim et al. · Journal of Clinical Oncology · 2010 · 661 citations

Medicine, Oncology, Pharmacology +13

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

Alain H. Rook, Joel M. Gelfand, Maria Wysocka et al. · Blood · 2015 · 221 citations · Full text

Medicine, Dermatology, Immunology +16

Topical Chemotherapy in Cutaneous T-cell Lymphoma

Stuart R. Lessin, Madeleine Duvic, Joan Guitart et al. · JAMA Dermatology · 2012 · 185 citations · Full text

Medicine, Dermatology, Pharmacology +16

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

Kenneth R. Carson, Scott D. Newsome, Ellen J. Kim et al. · Cancer · 2014 · 136 citations · Full text

Medicine, Hematology, Pharmacology +16